These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 12820438

  • 1. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
    Tan DF, Li Q, Rammath N, Beck A, Wiseman S, Anderson T, al-Salameh A, Brooks J, Bepler G.
    Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
    [Abstract] [Full Text] [Related]

  • 2. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, Kuzumaki N, Kawakami Y, Benedict WF.
    Cancer; 1997 Apr 01; 79(7):1329-37. PubMed ID: 9083154
    [Abstract] [Full Text] [Related]

  • 3. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Ai Zheng; 2004 Jul 01; 23(7):845-50. PubMed ID: 15248926
    [Abstract] [Full Text] [Related]

  • 4. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.
    Lung Cancer; 2009 Mar 01; 63(3):410-7. PubMed ID: 18620780
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ.
    Clin Cancer Res; 1997 Jan 01; 3(1):87-93. PubMed ID: 9815542
    [Abstract] [Full Text] [Related]

  • 7. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, Fujisawa T.
    Cancer; 2007 Jun 15; 109(12):2506-14. PubMed ID: 17487846
    [Abstract] [Full Text] [Related]

  • 8. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer.
    Jung CK, Jung JH, Park GS, Lee A, Kang CS, Lee KY.
    Pathol Int; 2006 Sep 15; 56(9):503-9. PubMed ID: 16930330
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
    Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F, Mottolese M.
    Eur J Surg Oncol; 2008 May 15; 34(5):593-8. PubMed ID: 17693049
    [Abstract] [Full Text] [Related]

  • 11. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients.
    Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G.
    Clin Cancer Res; 2001 Aug 15; 7(8):2468-74. PubMed ID: 11489828
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
    Hirabayashi H, Ohta M, Tanaka H, Sakaguchi M, Fujii Y, Miyoshi S, Matsuda H.
    J Surg Oncol; 2002 Dec 15; 81(4):177-84; discussion 184. PubMed ID: 12451621
    [Abstract] [Full Text] [Related]

  • 13. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, Yoshimatsu T, Kodate M, Uramoto H, Mizoue T, Yano K, Yasumoto K.
    Anticancer Res; 2000 Dec 15; 20(1B):505-10. PubMed ID: 10769714
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
    Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY.
    Clin Cancer Res; 2002 Dec 15; 8(12):3796-802. PubMed ID: 12473592
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.
    Lung Cancer; 2004 Oct 15; 46(1):77-85. PubMed ID: 15364135
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M.
    Anticancer Res; 2003 Oct 15; 23(3C):2829-36. PubMed ID: 12926120
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z, Ma J, Li N, Sun N, Wang C.
    Ann Thorac Surg; 2006 Jul 15; 82(1):243-8. PubMed ID: 16798222
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer.
    Shibata Y, Hidaka S, Tagawa Y, Nagayasu T.
    Anticancer Res; 2004 Jul 15; 24(3b):1925-8. PubMed ID: 15274378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.